Tablets: Each tablet contains 5 mg Nicergoline (I.N.N.).
Excipients: Sucrose, calcium phosphate, sodium carboxymethyl cellulose,
micro-crystalline cellulose, magnesium stearate, gum arabic, titanium dioxide,
magnesium carbonate, flora wax, talc and Pal Super orange. Drops: Each ml (20
drops) of prepared solution contains: 5 mg Nicergoline (I.N.N.), lactose,
tartaric acid, methyparaben and water.
Sermion (nicergoline) is a vasoactive
pharmaceutical product, synthesized in Farmitalia research laboratories, with
alpha-adrenolytic action to activate the brain's metabolism. Sermion (nicergoline)
acts on different levels:
On the cerebral level, it prompts a lowering of
vascular resistance, an increase in arterial flow and the use of oxygen and
glucose. In terms of lung circulation, it lowers vascular resistance. With
regard to limb circulation, it brings about an increase in the flow,
particularly evident in those patients with insufficient irrigation due to
Studies carried out in vitro and in vivo, both
experimental and on human beings, have shown that Sermion (nicergoline) inhibits
platelet aggregation. Sermion (nicergoline) has proved to be effective in
hospital use, regulating and improving brain disorders caused by
metabolic-vascular insufficiency and alterations derived from insufficient
arterial irrigation in the limbs. When the therapeutic dosage is administered,
Sermion (nicergoline) does not affect arterial tension. In the case of patients
suffering from hypertension, it may induce a gradual lowering of tension.
This pharmaceutical product does not induce
Acute and chronic cerebral metabolic-vascular
disorders (cerebral arteriosclerosis, thrombosis and cerebral embolism,
transitory cerebral ischaemia). Acute and chronic peripheral metabolic-vascular
disorders (organic and functional arteriopathies of the limbs), Raynaud's
disease and other syndromes caused by altered peripheral irrigation.
Migraines of vascular origin
Coadjutant therapy in clinical situations
accompanied by platelet hyper-aggregability, arterial tension
Corio-retinal vascular disorders: retinal
thromboses, diabetic retinopathy, macular degeneration and retinal
angiosclerosis Oto-vestibular problems of a vascular nature: dizziness, auditory
By mouth: 5-10 mg (1-2 tablets or 20-40 drops) 3
times daily at regular intervals over prolonged periods of time. To facilitate
absorption, take this medicine between meals.
The dosage and length of treatment are to be
decided by your doctor. At times, the therapeutic effects of Sermion (nicergoline),
both subjective and objective, are not immediately noticeable, but will be noted
after a certain period of treatment.
Directions For Using Drops
Pour the powder into the vial containing the
solvent and shake until completely dissolved.
To measure out Sermion (nicergoline) in drops,
use the accompanying syringe, sucking in the amount of liquid required for each
Although toxicology studies have not shown
nicergoline to have any teratogenic effect, the use of this medicine during
pregnancy should be limited to those cases where it is absolutely necessary.
The vasoactivity of Sermion (nicergoline) may
heighten the effect of pharmaceutical products that produce hypotension.
Although very infrequently, rubeosis, a hot
feeling, mild gastric upsets, hypotension and dizziness have been observed.
Should you notice any adverse reaction not described, consult your doctor or
Intoxication And Treatment
The chances of intoxication as a result of taking
this product are very remote. Only in certain cases of overdose can the symptoms
described under “Adverse Effects” appear. These subside if one stops taking
In cases of overdose or accidental ingestion,
consult the Toxicology Information Service.
Tablets: 45-tablet container. Drops: Container
with 1 vial of powder and 1 bottle of solvent.
This medicine must not be used after the expiry
date printed on the container.
Drops: Once prepared, the solution is good for 30
days at room temperature.
Keep this and all other medicines safely out of
the reach of children.